Table 2 Deconvolution of NAbs in serum of patients after interferon-based treatment and clearance of chronic HCV infection

From: Serum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C

Pt

HCV genotype of patient

Year after start of treatment

Neutralization breadth [number of HCVpp neutralized]

Reference monoclonal antibodies

Statistics

AR1A

HC-1

HEPC98

CBH-2

AR3A

HEPC74

HC84.26

AR4A

Pearson

P value

1

1a

−0.24

13

0.23

 

0.16

  

0.25

 

0.27

0.8063

3.0 × 105

0.98

10

  

0.27

  

0.25

 

0.35

0.7946

4.8 × 105

4.82

10

0.2

 

0.14

 

0.12

0.28

 

0.25

0.7592

1.6 × 104

7.18

5

0.11

 

0.24

    

0.43

0.7433

2.6 × 104

2

1a

−1.05

19

0.31

 

0.17

 

0.11

0.16

 

0.25

0.769

1.1 × 104

0.92

19

0.37

    

0.28

 

0.25

0.8515

3.7 × 106

3.67

16

  

0.18

 

0.11

0.11

 

0.55

0.6328

3.6 × 103

7.06

7

  

0.31

    

0.54

0.7515

2.0 × 104

3

1a

−0.21

18

    

0.34

  

0.49

0.7659

1.3 ×104

0.93

17

  

0.15

 

0.16

  

0.6

0.8296

1.1 × 105

3.28

17

  

0.24

 

0.17

0.11

 

0.48

0.8185

1.8 × 105

9.25

13

  

0.2

 

0.19

0.25

 

0.29

0.7819

7.6 × 105

4

1a

−1.97

17

   

0.11

 

0.35

0.27

0.21

0.9199

2.5 × 108

0.98

7

  

0.11

 

0.16

0.28

 

0.41

0.8367

7.9 × 106

5

1b

−0.98

18

   

0.14

  

0.26

0.49

0.8461

5.0 × 106

0.92

17

  

0.14

0.12

  

0.31

0.26

0.871

1.2 × 106

4.95

13

  

0.22

0.22

   

0.55

0.7394

2.9 × 104

9.11

9

  

0.23

0.17

   

0.54

0.7576

1.7 × 104

6

2

−1.00

15

     

0.51

0.14

0.35

0.5702

1.0 × 102

0.99

14

0.12

 

0.19

  

0.11

 

0.5

0.6886

1.1 × 103

5.83

7

  

0.31

    

0.59

0.6927

1.0 × 103

7

2b

0.24

12

  

0.23

0.16

   

0.57

0.6611

2.0 × 103

0.96

5

       

0.84

0.7857

6.7 × 105

2.92

5

    

0.34

 

0.11

0.55

0.6179

4.8 × 103

8

2b

−1.09

18

    

0.18

0.22

0.22

0.35

0.8558

2.9 × 106

1.11

16

     

0.16

0.26

0.34

0.8975

1.8 × 107

4.19

16

  

0.14

 

0.2

0.16

 

0.42

0.8008

3.8 × 105

9.75

11

   

0.29

 

0.5

 

0.21

0.5249

2.1 × 102

13.64

9

 

0.17

 

0.19

 

0.18

 

0.43

0.8026

3.5 × 105

9

2a

−1.09

5

  

0.15

  

0.27

 

0.5

0.7498

2.1 × 104

10

2b

−1.07

17

0.11

 

0.28

  

0.21

 

0.3

0.789

5.9 × 105

0.93

11

  

0.26

 

0.12

  

0.62

0.751

2.1 × 104

9.27

4

  

0.29

 

0.22

  

0.38

0.7417

2.7 × 104

11

2a

−0.12

13

  

0.23

 

0.18

  

0.53

0.7519

2.0 × 104

1.00

9

  

0.15

    

0.77

0.7044

7.6 × 104

12

3b

−0.05

14

  

0.24

    

0.56

0.7135

6.0 × 104

1.10

6

  

0.29

  

0.15

 

0.41

0.7833

7.2 × 105

3.84

4

  

0.36

    

0.48

0.711

6.4 × 104

13

3b

−0.46

15

 

0.13

0.13

 

0.25

0.32

 

0.17

0.7497

2.1 × 104

0.88

7

 

0.12

0.25

  

0.19

 

0.29

0.7521

2.0 × 104

4.41

5

  

0.25

    

0.54

0.6574

2.2 × 103

14

3a

−2.20

9

  

0.12

   

0.16

0.55

0.7228

4.7 × 104

1.10

7

  

0.22

    

0.65

0.6728

1.6 × 103

15

3a

0.92

5

 

0.13

0.39

   

0.11

0.32

0.7322

3.6 × 104

2.26

5

 

0.14

0.4

    

0.41

0.7754

9.6 × 105

16

3a

−0.39

16

  

0.11

 

0.13

0.35

 

0.25

0.8744

9.8 × 107

0.90

12

  

0.25

 

0.12

0.25

 

0.32

0.8278

1.2 × 105

5.73

10

  

0.29

 

0.13

  

0.45

0.7591

1.6 × 104

13.52

5

  

0.25

  

0.15

 

0.41

0.736

3.2 × 104

  1. Values are the proportion of each serum neutralization response attributed to each reference mAb, using a previously described deconvolution approach (10). Proportions greater than 0.1 are shown. The neutralization breadth is the number of 19 HCVpp that are neutralized greater than 50% by a 1:100 dilution of serum. P values are for Pearson correlation between serum sample neutralization profile and the best-fit combined reference mAb neutralization profile.
Back to article page